2月27日，A股市场震荡上行，创新药板块承压，科创创新药ETF汇添富（589120）微跌0.25%，资金持续逆势涌入，科创创新药ETF汇添富 （589120）已连续3日强势吸金超2800万元！ 科创创新药ETF汇添富（589120）标的指数成分股涨跌不一，康诺希涨超6%，博瑞医药涨超4%，益方生物涨超3%，皓元生物等上涨，百济神州、 百利天恒等回调。 【科创创新药ETF汇添富（589120）标的指数前十大成分股】 | 序号 | 代码 | 名称 | 申万一级行业 | 涨跌幅 | 估算权重 | | --- | --- | --- | --- | --- | --- | | 1 | 688235 | 百济神州-U | 医药生物 | -2.18% | 10.19% | | 2 | 688578 | 艾力斯 | 医药生物 | -0.02% | 9.07% | | 3 | 688506 | 百利天恒 | 医药生物 | -4.18% | 8.25% | | 4 | 688180 | 君实生物-U | 医药生物 | 0.18% | 6.60% | | 5 | 688331 | 荣昌生物 | 医药生物 | -0.33% | 6 ...

Core Insights - The article discusses the groundbreaking development of brain-computer interface (BCI) technology by Synchron, which allows ALS patients to control Apple devices using their thoughts, marking a significant advancement in assistive technology [3][4][5]. Group 1: Technology Overview - Synchron's Stentrode is a minimally invasive brain-computer interface that captures neural signals through a micro-stent implanted in the brain's blood vessels, enabling users to control digital devices [3][5][18]. - The BCI HID (Brain-Computer Interface Human Interface Device) protocol introduced by Apple integrates brain signals as a native input method alongside touch, keyboard, and voice, facilitating a new form of interaction with Apple devices [7][11][21]. - The system provides visual feedback to users, allowing them to see the strength of their neural signals and make precise selections on their devices [11][13]. Group 2: User Experience - Mark Jackson, an ALS patient, is one of the first users of Stentrode, and he has reported significant improvements in his ability to interact with technology, including sending messages and controlling applications [9][30]. - The integration of AI, such as GPT-4o, enhances the BCI experience by predicting user needs and providing contextual options, making the interaction more intuitive and efficient [26][29][32]. - Synchron aims to make BCI technology as ubiquitous as keyboards and mice, focusing on improving the quality of life for individuals with severe mobility impairments [9][21][33]. Group 3: Market Potential - There are approximately 150,000 potential users in the U.S. with severe upper limb disabilities who could benefit from BCI technology, highlighting a significant market opportunity for Synchron [33]. - The global prevalence of spinal cord injuries, which affects around 15.4 million people, further underscores the demand for innovative assistive technologies like BCI [33][35]. Group 4: Competitive Landscape - Synchron's approach contrasts with Neuralink's invasive methods, as Stentrode offers a safer, less risky alternative for patients who cannot undergo traditional brain surgery [14][21][22]. - The collaboration between Synchron and Apple is seen as a pivotal moment in the BCI field, emphasizing the importance of safety and user experience in technology development [21][33].

Group 1 - Apple is collaborating with brain-computer interface company Synchron to develop technology that allows patients with spinal cord injuries or ALS to control iPhones using their thoughts [2][10][32] - The technology involves a device called Stentrode, which is implanted in the brain and reads neural signals to translate them into actions on devices [6][8][10] - Stentrode connects with Apple's existing accessibility feature, Switch Control, enabling brain signals to be recognized as valid input for controlling devices [7][8] Group 2 - The Stentrode device is currently in testing and has shown promising results, allowing some patients to operate Apple devices for the first time [10][11] - The technology is less invasive compared to other brain-computer interfaces, as it does not require opening the skull, thus reducing surgical risks [24][34] - Synchron's approach contrasts with Neuralink's invasive methods, focusing on safety and accessibility for patients who cannot undergo traditional surgeries [32][34] Group 3 - Synchron has integrated AI technology, such as GPT-4o, to enhance the functionality of its brain-computer interface, allowing for more intuitive user interactions [40][44] - The AI integration enables multi-modal input, providing users with options based on predicted thoughts, thus improving communication for those with severe disabilities [43][44] - The ultimate goal of Synchron's technology is to create a more natural interaction between users and devices, allowing individuals with disabilities to regain a sense of independence [55][66] Group 4 - As of now, Synchron has implanted Stentrode in 10 patients, with a significant potential user base estimated at 150,000 in the U.S. alone due to severe upper limb disabilities [60][61] - The global prevalence of spinal cord injuries is approximately 15.4 million, indicating a substantial market for brain-computer interface technologies [61] - Apple's plans to release a new software interface for third-party developers will further promote the integration of brain-controlled technology within its ecosystem [59]